CONFIDENTIAL

OCON
HEALTHCARE

Board of Directors
Dec. 15, 2021

Dear OCON shareholders,
As traditionally done every quarter post OCON's Board meeting – I'm happy to share with you all our summary demonstrating our continued progress and work towards bringing our assets to fruition.
2021 was an extremely challenging year but we have prevailed with financing, platform progress and additional KOLs and incredible team members that make our company so resilient!

To remind you all, we are in a CLA (convertible) round (pre-Series B financing round). Since we have already gained momentum on this CLA we will be decreasing the discount shortly, If any of you wish to take part in this round you are welcome to contact me and/or Amir our CFO to discuss details and conditions, we would also be happy for any introductions or thoughts you have for supporting this effort.

My personal regards to each and every one of you and best wishes for a happy, healthy and **FEMstastic** 2022!

https://www.linkedin.com/feed/update/urn:li:activity:6879481917029281794

Best Wishes,
Keren Leshem and the OCON Team

OCON

AGENDA

1 Corporate Updates
- IP Update

2 IUB™ Ballerine®
- Distribution Status
- FDA/IND Submission progress
- Marketing Update

3 The SEAD™
- R&D update
- Scientific Oral Presentations
- Clinical (PH2a & PH2b) update

4 Therapeutic IUB™
- R&D Status

5 Finances
- 2021 workplan and financial summary
- 2022 workplan

ANNEX
- Updated Corporate Deck slides (non Confidential)

OCON

IP UPDATE

OCON's ROBUST PRODUCT FRANCHISE PROTECTED BY **STRONG IP**

FILING of SEAD PCT

PATENT FAMILY #1

INTRAUTERINE DEVICE PLATFORM

Granted
in USA, EU, Canada, China and Israel

PATENT FAMILY #2

FOCUS ON BEADS (ANY SHAPE)

Granted
in USA, Dec.2020
other territories pending

PATENT FAMILY #3



FOCUS ON SPECIFIC COMPOSITION (OF BEADS)

Patent Pending

OCON

DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOF

PCT Appl. No. PCT/IB2021/058603 based on U.S. Provisional No. 63/081,028
Filing Date: September 21, 2021

Discloses a delivery vehicle for a silver ion source, such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, which comprises a plurality of beads bearing a tissue cauterizing amount of a silver ion source.

Independent claims:

1. An intrauterine device comprising:

- a wire having a portion capable of forming an elastically deformable three-dimensional structure;
  wherein the three-dimensional structure:
  a) is elastically deformable to a partially collapsed configuration;
  b) has a crush force of at least 15 grams/cm2; and
  c) is configured to elastically contract and expand in response to contraction and expansion of the uterine cavity,
- a plurality of beads, comprising:
  80% to 98% by weight of formulated active materials,
  wherein the formulated active materials comprise 75% to 100% by weight of silver nitrate and 0% to 25% by weight of potassium nitrate,
  wherein the ratio of potassium nitrate to silver nitrate is from 1:19 to 1:3,
  2% to 20% by weight of a hydroxy propyl cellulose binder; and
- two fixing beads, each positioned at opposite ends of the wire

15. A method of treating uterine-related disorders, comprising the steps of:

- administering a plurality of beads to a uterine cavity of a human patient in need comprising:
  i. from 75% to 100% by weight of silver nitrate and 0% to 25% by weight of potassium nitrate; and
  ii. from 2% to 20% by weight of a hydroxy propyl cellulose binder; and
- maintaining the plurality of beads in contact with an endometrial lining of the uterus for a time period sufficient to necrose endometrial tissue.

OCON

DISTRIBUTION STATUS

IUB™ Ballerine® **DISTRIBUTION** UPDATE



TAIWAN

Approval (2YR indicated)
Launch Q1 2022

SOUTH AMERICA

Order Placed
Launch Q1 2022

CANADA

Order Placed
Launch Planned Q2 2022

JAPAN

Regulatory Submission
~24 months

OCON

IUB™ Ballerine® **DISTRIBUTION** UPDATE IL

משרד הבריאות
חטיבת טכנולוגיות רפואיות, מידע ומחקר
אגף ציוד רפואי
מדינת ישראל

אישור רישום בפנקס הציוד הרפואי

ניתן בזאת אישור , כי בהתאם לבקשת רישום מס : 27670002
הציוד הרפואי (אביזרים / מכשירים רפואים (אמ"ר)) הבא :

שם הציוד הרפואי	התקן תוך רחמי בלרין
דגמים	
יעוד הציוד הרפואי	מניעת הריון הפיכה ארוך טווח
התויה	. גניקולוגיה - התקן תוך רחמי משולב נחושת למניעת הריון לנשים החל מגיל
שם בעל הרישום וכתובתו	. ; השדרה המרכזית ת.ד. , מודיעין ;
שם היצרן וכתובתו	אוקון מדיקל ; השדרה המרכזית ; ישראל
שם אתר היצור וכתובתו	. אוקון מדיקל - השדרה המרכזית מודיעין -

התניות

הנחיות
- לפי הוראות היצרן שאושרו ע"י גוף המאשר: (אישורי איכות בלבד)
- מאושר לשימוש בהתאם להוראות היצרן, כפי שאושרו ע"י הגוף המאשר.
- השימוש מוגבל לרופא שהוזדרך והוסמך ע"י היצרן (או ע"י נציג מטעמו שהוסמך על ידו) בבית חולים ובמרפאה בלבד.

התניות לרישום זמני
- על בעל הרישום לעדכן את משרד הבריאות לא יאוחר מה - על החלטותו בתחום הרגולטורי: האם בכוונתו לבקש להעביר את אישור הרישום בישראל כך שיהיה ע"פ אישורי ו/ או / אחר

נרשם בפנקס הציוד הרפואי (האמ"ר) במשרד הבריאות.
תוקף האישור לשיווק הציוד הרפואי (האמ"ר) הינו ליעודים ולהתוויות המתוארים לעיל בלבד.
האישור בתוקף עד : 31/08/2022

משרד הבריאות מדינת ישראל אמ"ר אביזרים ומכשירים רפואיים MEDICAL DEVICES MINISTRY OF HEALTH STATE OF ISRAEL

ד"ר נדב שפר
מנהל אגף ציוד רפואי

חתימה | תאריך חתימת האישור | שם ותפקיד המאשר

IL AMAR APPROVAL GRANTED

(non-CE)

מאוחדת
משנים את עולם הבריאות בישראל

1ST HMO Agreement

Meuhedet HMO - premium complementary insurance

2021 sales



Regrowth after summer vacations and holidays

OCON

IUB™ Ballerine® **REGULATORY** STRATEGY

Remove CE linkage from local country requirements & Sales push non-CE Markets

X

Austria, Baltics, Belgium, Bulgaria, Czech Republic, Croatia, Cyprus, Denmark, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Netherlands, Norway, Nordics, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

✔

Audit in March 2022

- Australia
- Brazil
- Canada
- Japan
- ~~U.S. *(Medical Devices)*~~

NO

CE

REQUIRED

✔

Local Registrations

- Israel (AMAR Approval)
- LATAM (5 Approvals)
- Asia (Taiwan Approval)
- Africa (South Africa)
- UK
- ~~Switzerland~~

OCON

IUB™ Ballerine® **REGULATORY** STRATEGY

EU MDR

x

Austria, Baltics, Belgium, Bulgaria, Czech Republic, Croatia, Cyprus, Denmark, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Netherlands, Norway, Nordics, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

Other IUD manufacturers announced they will not file for MDR:

- Goldluna
- PrimediFem IUDs



Rumors Bayer is selling their European Women's Health Division

BAYER

OCON

IUB™ Ballerine® IND SUBMISSION status FDA

PRE-IND submission activities:

June 21	July 21	August 21	Sept./Oct. 21
GAP Analysis DONE	IND - Project initiation	real world data statistical analysis finalization	draft clinical protocol **Submission**: real-world data article (peer review)

IND Submission: *UPDATED TIMELINE*

~~October 21~~ **now Jan.22**	~~Nov 21~~ - ~~Jan 22~~ **now Dec 21 March 21**	~~Feb 22~~ **now March 22**	**April 22**
Submission: clinical protocol** **#IND kick-off**	**IND preparation** writing, meetings, ad hoc RA support	**#IND Submission**	**FDA response (approval)**

OCON

U.S. IND KOL ADDITIONS

Jeff Peipert, MD

Clarence E. Ehrlich Professor and Chair of Obstetrics and Gynecology at Indiana University School of Medicine. Principal Investigator of the Contraceptive **CHOICE** Project, which recruited 9,256 women and successfully followed them for 2-3 years for contraceptive effectiveness, satisfaction, and continuation rates among other numerous studies.

INDIANA UNIVERSITY SCHOOL OF MEDICINE

Alisa Goldberg, MD

Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Vice President of Research and Clinical Training at Planned Parenthood League Massachusetts. Founded and currently directs the Division of Family Planning and Family Planning Fellowship program at BWH and the Department of Research at Planned Parenthood League of Massachusetts. Currently serves as the Chair on the Family Planning Fellowship Advisory Board. Recently recognized for this work with the 2019 Society of Family Planning Mentor Award.

HARVARD UNIVERSITY

Andrea Lukes, MD

An experienced principal investigator in industry-sponsored, NIH and CDC clinical trials, overseen more than 80 clinical trials of investigational women's health products, including both drugs and devices, in the last ten years. Published extensively in leading obstetrics and gynecology journals. Served on advisory committees for FDA meetings on the clinical development of a variety of women's health products. Founded the Carolina Women's Research and Wellness Center. Co-founded and served as the Director of Gynecology for the Women's Hemostasis and Thrombosis Clinic at the Duke University Medical Center.

Duke UNIVERSITY Health Decisions

OCON MARKETING UPDATE

Speaking Engagements | Panels | Presentations | Podcasts

Finalist: Women Innovators
EU Prize 21 Out of hundreds of applications

Tel-Aviv University Healthcare Innovation Course
Keynote Presentation ~60 participants

OCON

IUB™ SEAD™

Spherical **E**ndometrial
Ablation **D**evice

OCON

SEAD™ Global Endometrial Ablation Therapy

Phase II Clinical Studies

ABNORMAL UTERINE BLEEDING

R&D UPDATE

Clinical batch – ready to go!

44 units – Batch release tests are within specifications

Outer Pack
Carton box

Secondary
Aluminum pouch under vacuum
Light & moisture protected

Primary
Sterile Tyvek pouch

Feature	Specification	
Tensile force	>12N	☑
EtO residuals	0.163mg/device	☑
LAL	<0.1EU/device	☑
Product weight	1.0046g	☑
Active material weight	0.8082g	☑
Product diameter	16.12mm	☑
Cylinder weight	0.03g	☑
Cylinder diameter	2.70mm	☑
Dissolution kinetics	106% at 30min	☑

(All numbers are averages)

OCON

IUB™ SEAD™

Scientific Oral Presentations & Publications

FIGO XXIII World Congress of Gynecology and Obstetrics October 2021

Certificate of Presentation

This is to certify that

Sergio Haimovich

Presented

A Novel Intra Uterine Ball: Spherical Endometrical Ablation Device

as an Oral Presentation at

XXIII FIGO World Congress of Gynecology and Obstetrics

which took place virtually, 21–28 October 2021

Dr Carlos Füchtner
FIGO and Congress President
XXIII FIGO World Congress of Gynecology and Obstetrics

Dr André Lalonde
Chair, Congress Organising Committee
XXIII FIGO World Congress of Gynecology and Obstetrics

Prof. Mary Ann Lumsden
FIGO Chief Executive

FIGO International Federation of Gynecology and Obstetrics
the Global Voice for Women's Health

FC13.6

SAFETY AND EFFICACY OF THE IUB SEAD™

THEME: AB 3 GENERAL GYNAECOLOGY/SUB-THEME: AB 3.4 BENIGN CONDITIONS IN GYNAECOLOGY

Sergio Haimovich[1]; Daniela Schardinger[2]

[1]Gynecology and Obstetrics Department Del Mar University Hospital, Cádiz, Spain, [2]Ocon Healthcare, Modiin, Israel

Objectives: The aim of this study is to assess the safety and efficacy of the IUB SEAD™ (Intra Uterine Ball: Spherical Endometrial Ablation Device) introducing silver nitrate to the uterus in women suffering from abnormal uterine bleeding. We present results of 6 months follow up period post treatment.

Methods: The IUB SEAD™ is a novel spherical endometrial ablation device that relies on the ablative action of silver nitrate and was designed to treat HMB, affecting at least 10–35% of women worldwide and adversely impacting quality of life - frequently leading to iron deficiency and related anemia. The study was performed in the outpatient clinics of 2 Bulgarian medical centres between September 2019 and December 2020. 16 women with HMB(PBAC>150) at least 3 months before inclusion were enrolled.

Results: A total of 16 participants aged 37–50 (mean=43) were enrolled with a mean baseline PBAC score of 424; 14 of 16 completed follow up requirements and were evaluable at 6 months. All procedures were completed successfully without device/procedure-related adverse events. At 6 months post-treatment the mean PBAC score was 95 with 55% of the overall cohort ≤75 and 72% ≤ 100 and a mean percentage of 83% reduction. The mean procedure related pain score was ≤2 (mild).

Conclusions: The IUB SEAD™ device is safe and effective in treating HMB in an outpatient environment. Future studies with larger number of patients are planned.

FIGO XXIII 24-29 OCTOBER 2021 SYDNEY, AUSTRALIA WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS

Volume 155, Issue S2

Special Issue: Abstracts of the XXIII FIGO World Congress of Gynecology & Obstetrics

Pages: 1-562
October 2021

ELSEVIER Journal of Minimally Invasive Gynecology Volume 28, Issue 11, Supplement, November 2021, Pages S63-S64

JMIG AGL 2021 ABSTRACTS

50TH GLOBAL CONGRESS ON MIGS AGL 2021 NOVEMBER 14-17 • Austin, Texas

Open Communications 12: Research

Iub™ Sead™ - A Novel Intra Uterine Ball: Spherical Endometrial Ablation Device

S Haimovich [1], MG Munro [2]

Study Objective: The aim of this study is to assess the safety and efficacy of the IUB SEAD™ (Intra Uterine Ball: Spherical Endometrial Ablation Device) introducing silver nitrate to the uterus in women suffering from abnormal uterine bleeding. We present results of 6 months follow up period post treatment. **Design:** Open-label multicenter study to assess the safety and efficacy of the IUB SEAD™ device in premenopausal women with predictable men-strual cycles, who suffer from AUB. Women with HMB were enrolled who had an average pictorial blood loss assessment chart (PBAC) score ≥ 150 over for 3 months. **Setting:** The study was performed in the outpatient clinics of 2 Bulgarian medical centres between September 2019 and December 2020. Patients or Participants: 16 women with HMB (PBAC>150) at least 3 months before inclusion were enrolled. **Interventions:** Eligible subjects who met all the inclusion/exclusion crite-ria were treated during the first 7 days following the cessation of menses. The SEAD™ device was inserted into the uterine cavity via vaginal approach. The device was left in the uterus for 30 (§5) minutes and then removed. **Measurements and Main Results:** A total of 16 participants aged 37-50 (mean = 43) were enrolled with a mean baseline PBAC score of 424; 14 of 16 completed follow up requirements and were evaluable at 6 months. All procedures were completed successfully without device/procedure-related adverse events. At 6 months post-treatment the mean PBAC score was 95 with 55% of the overall cohort ≤75 and 72% ≤ 100 and a mean percentage of 83% reduction. The mean procedure related pain score was ≤2 (mild).* **Conclusion:** The IUB SEAD™ device is safe and effective in treating HMB in an outpatient environment. Future studies with larger number of patients are planned. *Results may vary until presentation date.

OCON

SEAD CLINICAL UPDATE

IUB™ SEAD™ RED Study
Revolutionary Endometrial Device

OCON

IUB™ SEAD™ PH2a CLINICAL STUDY

Preliminary results: PBAC comparison between Baseline and Current (n=14)



once and done treatment

83% avg. Drop in PBAC

95% reported QoL satisfaction

PH2b initiation in July 2021

OCON

RED STUDY – Progress



RED STUDY – Study Flow (Following FDA Protocol)



RED STUDY (PH2b) – Recruitment status

- **2 patients** have **signed an informed consent** form:
  - started the **2 months PBAC screening phase**
  - expected procedure during **January 2022**

- **Additional 4 patients screened**

- Recruitment efforts* to complete
  10-15 patients enrolled by the end of 2021

*Recruitment efforts demonstrated in next slides

RECRUITMENT EFFORTS: COMMUNITY PHYSICIANS CONFERENCE



Lecture held by Prof. Haimovich
on October 19th to more than 150 local Israeli community physician in order to raise interest in the RED study and recruitment efforts

תודה רבה על השתתפותכם בהרצאה של פרופסור חיימוביץ בכנס
ועל התגובות הנלהבות מהחדשנות שלכם

משמח לשיתוף הפעולה שלכם בקהילה לאיתור מועמדות פוטנציאליות לניסוי!

E-mail with a link to the presentation
was sent following the lecture, to all mail list received by the Israeli association together with information on Study and relevant sites

RED STUDY MARKETING

www.oconmed.com/red

1 in 3 women

experience pain, **heavy bleeding,** fatigue & depression associated with Heavy Menstrual Bleeding

ACOG

Heavy / Abnormal Menstrual Bleeding

70% of all OBGYN consults

in the peri-menopausal & post-menopausal years

Minerva Surgical

79% of women

want treatments that do not involve surgery

Minerva Surgical

28% of women

missed work due to symptoms from Heavy Menstrual Bleeding

Borah BJ et al.



THERAPEUTIC IUB™

OCON

Therapeutic IUB – Q4 R&D Updates:

- ✓ Target Product Profile
- ✓ Selection of Contract Development & Manufacturing Organization (CDMO)
- ✓ Contract signed, kickoff January 2022
- ✓ Grant submission Israeli Innovation Authority: Expected submission Dec. 2021
  ~$500K Grant | Total budget: $1M

LNG-IUB R&D Activities

1st Prototype
Mar 31

Regulatory Gap analysis
Sep 30

2022

Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec

Prototype

Continued development

Nitinol Frame improvement - inhouse

Frame development - outsource

Single hand Inserter adaptation

Due H1/2022

- LNG-IUB 1st prototype (March/April 2022)
- Frame development: design for integral loop (pull-strings)
- Continued Prototype development

OCON

CDMO Selection | Out of 4 companies

SEVER PHARMA SOLUTIONS

Lubrizol

POLYZEN

ProMed Molding for Life

Experience LNG-IUD

R&D scaleup

Quality system

Cost

Remote Audit Performed

ProMed Minneapolis, MN U.S.

ProMed Molding for Life

- ✓ Specialized in silicone molding and extrusion of combination products
- ✓ Women's health projects (IVR, IUDs)
- ✓ Experience in LNG-IUDs manufacture+ inhouse analytics
- ✓ R&D to commercial production
- ✓ Packaging & assembly
- ✓ FDA registered, BSI ISO13485:2003

OCON

FINANCES

OCON

TERM SHEET* FOR LICENSE AGREEMENT WITH BioGenuine

*Under negotiations

- Specialized in women's health
- Up front fees
- Territory: China, HK & Southeast Asia
- China Marketing approval fee
- Sales Royalties payment
- Co-development of IUB therapeutic alternatives (have own formulation (e.g. Fibroids)

OCON

2021 WORK PLAN SUMMARY – Planed Vs. Actual

- **Investment round Q1/2 – TS signed, not executed.**
- **Finalization of the SEAD™ phase IIa** ✓
- **Initiation of the SEAD™ phase IIb** ✓
- **Ballerine® FDA gap Analysis & Preparation** ✓
- **Single hand inserter prototype** ✓

OCON

2022 WORK PLAN PILLARS

- CLA Round Closure
  Open Series B investment round

- IUB Ballerine®
  FDA/IND approval
  Continued push in Non-CE markets

- SEAD™ Phase IIb Continued (IIa Finalized)

- IUB Therapeutic - Working prototype

OCON

OCON
HEALTHCARE

ANNEX

VALIDATED

IUB™ - INTRAUTERINE BALL **PLATFORM TECHNOLOGY**

Ballerine®

SEAD™

Therapeutics

Future Feature

Pillars	Indication	Product	R&D	Pre-Clinical	1st Woman	1st Approval	Market POC	Addressable Market
	IUB™ PLATFORM TECHNOLOGY	IUB™ (INTRAUTERINE BALL) 3D Intrauterine Drug-Delivery Platform — MARKET ACCEPTANCE PILOT STUDY 100K WOMEN						$35B
Birth Control	Non-Hormonal Contraception	Ballerine® 3D Copper IUD						$2B
Birth Control	Hormonal Contraception	Ballerine® 3D Hormonal IUD						$2.5B
Therapies	Heavy Menstrual Bleeding	SEAD™ Spherical Endometrial Ablation Device						$1B
Therapies	Abnormal Uterine Bleeding	OH-80						$5B
Therapies	Uterine Fibroids	OH-77						$2B
Therapies	Endometriosis	OH-32						$16B
Therapies	Menopause HRT	OH-94						$6.5B
Diagnostics	Dx & Detection AI Internal Wearable							

RECENT ACQUISITIONS

$1.1B CooperSurgical — *Paragard*

$310M BAYER — *Daré*

$240M ORGANON — *Alydia Health*

$954M ORGANON — *Forendo Pharma*

~$1B BAYER — *KaNDy*

$795M HOLOGIC — *Mobidiag*

IMARC Group | IMARC Group | Report Linker | Grand View Research | Report Linker | Fortune Business Insights | Grand View Research

OCON

RECENT WOMEN'S HEALTH **ACQUISITIONS**

2021 — 2020 — 2017

ORGANON + Alydia Health — **$240M** — Abnormal (PP) Uterine Bleeding

ORGANON + Forendo Pharma — **$954M** — Endometriosis

CooperSurgical + Generate Life Sciences — **$1.6B** — Reproductive Health

BAYER + KaNDy Therapeutics — **~$1B** — Menopause

BAYER + Daré Bioscience — **$310M** — Non-hormonal Contraception

CooperSurgical + Teva Paragard (Cu IUD) — **$1.1B** — Non-hormonal Contraception

OCON

- Reproductive Health Contraception

- Heavy & Abnormal Uterine bleeding

- Uterine Fibroids Cancers & Endometriosis
- Hormonal Therapies & Menopause

*Crunchbase

OCON

REVOLUTIONISING WOMEN'S HEALTH